Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

Open Access 01-08-2018 | Retinal Disorders

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy

Authors: Thomas J. van Rijssen, Elon H. C. van Dijk, Greet Dijkman, Camiel J. F. Boon

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 8/2018

Abstract

Purpose

To identify characteristics of Caucasian chronic central serous chorioretinopathy (cCSC) patients without a complete resolution of subretinal fluid (SRF) after reduced-settings photodynamic therapy (PDT), or with a recurrence of SRF after PDT.

Methods

Chronic CSC patients treated with reduced-settings PDT were divided into a successful PDT group and unsuccessful PDT group. Patients in the successful PDT group did not have any subretinal fluid (SRF) during follow-up after PDT, whereas the unsuccessful PDT group was categorized based on either persistence or recurrence of SRF after PDT treatment. Data on age, sex, best-corrected visual acuity (BCVA), PDT spot size, characteristics on fluorescein angiography (FA), indocyanine green angiography (ICGA), and optical coherence tomography (OCT) were obtained.

Results

Twenty-six patients in the successful PDT group (20 males, 6 females) had a mean age of 51 years (range, 25–78). In the unsuccessful PDT group, 20 males with a mean age of 60 years (range, 34–78) were included. At last visit before PDT, age, percentage of males, and percentage of patients with diffuse leakage > 1 optic disc diameter on FA were higher in the unsuccessful PDT group (p = 0.010, p = 0.029, and p = 0.008, respectively). At last visit before PDT, BCVA and the percentage of patients with intense hyperfluorescence on ICGA were lower in the unsuccessful group (p = 0.017 and p = 0.004, respectively). Patients with intense hyperfluorescence on ICGA were more likely (95% CI 1.3–333 times) to have a successful outcome (p = 0.045). A decrease in SFCT at final visit was observed in both groups (− 111 μm and p = 0.013, and − 141 μm and p = 0.007, respectively). BCVA only improved at final visit in the successful PDT group (5 Early Treatment of Diabetic Retinopathy Study letters, p < 0.001).

Conclusions

Chronic CSC patients with recurrent or persistent SRF after PDT are characterized by a higher percentage of males, more patients with diffuse leakage on FA, more patients without intense hyperfluorescence on ICGA, higher age, and lower pre-PDT and long-term BCVA than in the successful PDT group. A reduction in SFCT after PDT does not necessarily lead to complete resolution of SRF, while a resolution of SRF appears to be required to lead to a significant BCVA improvement in cCSC.

Breukink MB, Dingemans AJ, den Hollander AI, Keunen JE, MacLaren RE, Fauser S, Querques G, Hoyng CB, Downes SM, Boon CJ (2017) Chronic central serous chorioretinopathy: long-term follow-up and vision-related quality of life. Clin Ophthalmol 11:39–46. https://doi.org/10.2147/opth.s115685 CrossRefPubMed

Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, Jaisser F, Behar-Cohen F (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118. https://doi.org/10.1016/j.preteyeres.2015.05.003 CrossRefPubMed

Imamura Y, Fujiwara T, Margolis R, Spaide RF (2009) Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 29(10):1469–1473. https://doi.org/10.1097/IAE.0b013e3181be0a83 CrossRefPubMed

Nicholson B, Noble J, Forooghian F, Meyerle C (2013) Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 58(2):103–126. https://doi.org/10.1016/j.survophthal.2012.07.004 CrossRefPubMedPubMedCentral

Teussink MM, Breukink MB, van Grinsven MJ, Hoyng CB, Klevering BJ, Boon CJ, de Jong EK, Theelen T (2015) OCT angiography compared to fluorescein and indocyanine green angiography in chronic central serous chorioretinopathy. Invest Ophthalmol Vis Sci 56(9):5229–5237. https://doi.org/10.1167/iovs.15-17140 CrossRefPubMed

Chan SY, Wang Q, Wei WB, Jonas JB (2016) Optical coherence tomographic angiography in central serous chorioretinopathy. Retina 36(11):2051–2058. https://doi.org/10.1097/iae.0000000000001064 CrossRefPubMed

Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA (1996) Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 16(3):203–213CrossRefPubMed

Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S (2004) Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111(2):244–249. https://doi.org/10.1016/j.ophtha.2003.09.024 CrossRefPubMed

Cheng CK, Chang CK, Peng CH (2017) Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina 37(2):325–333. https://doi.org/10.1097/iae.0000000000001138 CrossRefPubMed

10.

Yannuzzi LA, Slakter JS, Gross NE, Spaide RF, Costa D, Huang SJ, Klancnik JM Jr, Aizman A (2003) Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 23(3):288–298CrossRefPubMed

11.

Salehi M, Wenick AS, Law HA, Evans JR, Gehlbach P (2015) Interventions for central serous chorioretinopathy: a network meta-analysis. Cochrane Database Syst Rev (12):Cd011841. doi:https://doi.org/10.1002/14651858.CD011841.pub2

12.

Lai TY, Wong RL, Chan WM (2015) Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 113:T8PubMedPubMedCentral

13.

Liu HY, Yang CH, Yang CM, Ho TC, Lin CP, Hsieh YT (2016) Half-dose versus half-time photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 167:57–64. https://doi.org/10.1016/j.ajo.2016.04.001 CrossRefPubMed

14.

Peng SY, Lai CC, Wang NK, Wu WC, Hwang YS, Chen KJ, Chen LJ, Tsai S, Chan WC, Liu L, Yeung L (2017) Real-world experience with half-time versus half-dose photodynamic therapy in chronic central serous chorioretinopathy. J Ocul Pharmacol Ther 33(6):466–472. https://doi.org/10.1089/jop.2016.0184 CrossRefPubMed

15.

Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK (2003) Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 87(12):1453–1458CrossRefPubMedPubMedCentral

16.

Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U (2002) Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefe’s Arch Clin Exp Ophthalmol 240(9):748–757. https://doi.org/10.1007/s00417-002-0517-4 CrossRef

17.

Tseng CC, Chen SN (2015) Long-term efficacy of half-dose photodynamic therapy on chronic central serous chorioretinopathy. Br J Ophthalmol 99(8):1070–1077. https://doi.org/10.1136/bjophthalmol-2014-305353 CrossRefPubMed

18.

Nicolo M, Zoli D, Musolino M, Traverso CE (2012) Association between the efficacy of half-dose photodynamic therapy with indocyanine green angiography and optical coherence tomography findings in the treatment of central serous chorioretinopathy. Am J Ophthalmol 153(3):474–480.e471. https://doi.org/10.1016/j.ajo.2011.08.015 CrossRefPubMed

19.

Breukink MB, Mohr JK, Ossewaarde-van Norel A, den Hollander AI, Keunen JE, Hoyng CB, Boon CJ (2016) Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol. Acta Ophthalmol 94(2):187–197. https://doi.org/10.1111/aos.12938 CrossRefPubMed

20.

Lai FH, Ng DS, Bakthavatsalam M, Chan VC, Young AL, Luk FO, Tsang CW, Brelen ME (2016) A multicenter study on the long-term outcomes of half-dose photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 170:91–99. https://doi.org/10.1016/j.ajo.2016.07.026 CrossRefPubMed

21.

Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLoS One 12(7):e0181479. https://doi.org/10.1371/journal.pone.0181479 CrossRefPubMedPubMedCentral

22.

Inoue R, Sawa M, Tsujikawa M, Gomi F (2010) Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 149(3):441–446.e441–442. https://doi.org/10.1016/j.ajo.2009.10.011 CrossRefPubMed

23.

Gregori NZ, Feuer W, Rosenfeld PJ (2010) Novel method for analyzing snellen visual acuity measurements. Retina 30(7):1046–1050. https://doi.org/10.1097/IAE.0b013e3181d87e04 CrossRefPubMed

24.

Matet A, Daruich A, Zola M, Behar-Cohen F (2017) Risk factors for recurrences of central serous chorioretinopathy. Retina. https://doi.org/10.1097/IAE.0000000000001729

25.

Fujita K, Imamura Y, Shinoda K, Matsumoto CS, Mizutani Y, Hashizume K, Mizota A, Yuzawa M (2015) One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmology 122(3):555–561. https://doi.org/10.1016/j.ophtha.2014.09.034 CrossRefPubMed

26.

Chen G, Tzekov R, Li W, Jiang F, Mao S, Tong Y (2017) Subfoveal choroidal thickness in central serous chorioretinopathy: a meta-analysis. PLoS One 12(1):e0169152. https://doi.org/10.1371/journal.pone.0169152 CrossRefPubMedPubMedCentral

27.

Gemenetzi M, De Salvo G, Lotery AJ (2010) Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 24(12):1743–1756. https://doi.org/10.1038/eye.2010.130 CrossRef

28.

Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF (2010) Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 117(9):1792–1799. https://doi.org/10.1016/j.ophtha.2010.01.023 CrossRefPubMed

29.

Wakatsuki Y, Shinojima A, Kawamura A, Yuzawa M (2015) Correlation of aging and segmental choroidal thickness measurement using swept source optical coherence tomography in healthy eyes. PLoS One 10(12):e0144156. https://doi.org/10.1371/journal.pone.0144156 CrossRefPubMedPubMedCentral

30.

Lin JB, Tsubota K, Apte RS (2016) A glimpse at the aging eye. NPJ Aging Mech Dis 2:16003. https://doi.org/10.1038/npjamd.2016.3 CrossRefPubMedPubMedCentral

31.

Wang MS, Sander B, Larsen M (2002) Retinal atrophy in idiopathic central serous chorioretinopathy. Am J Ophthalmol 133(6):787–793CrossRefPubMed

32.

Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A, Manea M (2005) The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol 139(1):87–99. https://doi.org/10.1016/j.ajo.2004.08.037 CrossRefPubMed

33.

Daruich A, Matet A, Marchionno L, De Azevedo JD, Ambresin A, Mantel I, Behar-Cohen F (2017) Acute central serous chorioretinopathy: factors influencing episode duration. Retina Oct 37(10):1905–1915. https://doi.org/10.1097/IAE.0000000000001443

Title: Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy
Authors: Thomas J. van Rijssen
Elon H. C. van Dijk
Greet Dijkman
Camiel J. F. Boon
Publication date: 01-08-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-018-4003-z

At a glance: The STEP trials

Springer Medicine

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2018

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

Correction to: Light localization with low-contrast targets in a patient implanted with a suprachoroidal–transretinal stimulation retinal prosthesis

Potential predictors for frequent relapse in human leukocyte antigen-B27-associated uveitis

Safety and long-term efficacy of repeated dexamethasone intravitreal implants for the treatment of cystoid macular edema secondary to retinal vein occlusion with or without a switch to anti-VEGF agents: a 3-year experience

Optical coherence tomography angiography in pachychoroid spectrum diseases

Fixation behavior in macular dystrophy assessed by microperimetry